{"id":"W3009755741","doi":"10.1200/jco.2007.25.18_suppl.5018","title":"Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Abbott (Canada); London Health Sciences Centre","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Hazard ratio; Urology; Prostate cancer; Internal medicine; Population; Randomized controlled trial; Surgery; Gastroenterology; Oncology; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003403939,0.001527396,0.002711636,0.0003171905,0.0005334589,0.000904467,0.0009272153,0.001615766,0.008456384],"category_scores_gemma":[0.002984623,0.0006628276,0.001656885,0.0003344941,0.001077493,0.0007866222,0.000334614,0.002597456,0.001002032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006410989,"about_ca_system_score_gemma":0.001334562,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006774014,"about_ca_topic_score_gemma":0.001484241,"domain_scores_codex":[0.9986402,0.0009041181,0.0000785377,0.000179458,0.00007813502,0.0001194973],"domain_scores_gemma":[0.9980573,0.0006888013,0.0004546544,0.0001595746,0.0001202041,0.0005194909],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9846376,0.00545491,0.0005378481,0.0002416793,0.0007369352,0.00002651096,0.00002480732,0.0001523841,0.001135522,0.00004904917,0.0004904882,0.006512392],"study_design_scores_gemma":[0.956919,0.04100227,0.001212179,0.00001135362,0.0003042047,0.00001601259,0.000007086516,0.0001314265,0.0001483812,0.0000521821,0.0001908111,0.000005116986],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846859,0.003542368,0.0008097637,0.0007440174,0.0004965414,0.005534601,0.001584611,0.000115535,0.002486641],"genre_scores_gemma":[0.984984,0.002061129,0.001684353,0.00117687,0.0003926735,0.005698331,0.001837853,0.00002432042,0.00214053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008456384,"threshold_uncertainty_score":0.02828938,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05724346998701832,"score_gpt":0.4716877208318873,"score_spread":0.4144442508448689,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}